SYNB
Putnam BioRevolution ETF
SYNB actively invests in companies of all sizes around the globe that enable biological innovation.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
5.2 M
ASSETS UNDER MGMT
70 bp
EXPENSES
Fund Basics
| Fund sponsor | Power Corporation of Canada |
| Category | Global |
| Asset class | Equity |
| Website | link... |
| Inception date | Sep 29, 2022 |
| Assets (mns) | $5 |
| Expense ratio | 70 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | Annually |
| Taxation | 1099 |
| Stock selection | Proprietary |
| Weighting | Proprietary |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| THERMO FISHER SCIENTIFIC INC | 7.9 % |
| DANAHER CORP | 7.6 % |
| NVIDIA CORP | 7.0 % |
| BIO-RAD LABORATORIES-CL A | 5.9 % |
| ALPHABET INC. CLASS A | 5.0 % |
| NOVOZYMES A/S-UNSPONS ADR | 4.8 % |
| CORTEVA INC | 4.4 % |
| ABBVIE INC | 4.3 % |
| REGENERON PHARMACEUTICALS | 4.2 % |
| ELI LILLY & CO | 3.7 % |
Constituent Breakdown
| Number of holdings | 36 |
| Herfindahl-Hirschman Index | 415 |
| Wgt avg mkt cap (mns) | $239,160 |
| Large cap (>$10bn) | 81.4% |
| Mid cap ($2-10bn) | 14.0% |
| Small cap (<$2bn) | 4.6% |
| Developed mkts. | 100.0% |
| Emerging mkts. | 0.0% |
Country Exposure
 |
UNITED STATES | 80.4 % |
 |
DENMARK | 8.2 % |
 |
BRITAIN | 3.0 % |
 |
GERMANY | 2.4 % |
 |
FRANCE | 1.7 % |
 |
NORWAY | 1.5 % |
 |
NETHERLANDS | 1.0 % |
Historical Performance
Standardized Performance (as of 10/31/2024)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | Incep. | |
|---|---|---|---|---|---|---|---|
| Total Returns | 5.6% | 23.8% | -- | -- | -- | -- | 6.2% | Volatility | 13.8% | 14.1% | 15.1% | -- | -- | -- | -- |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.15 | 87% |
| MSCI EAFE | 1.01 | 79% |
| MSCI Emg Mkts | 0.89 | 61% |
Liquidity Measures
| Avg. volume (000) | 0 |
| Turnover | 0.0% |
| Avg. Bid/Ask (% of price) | 0.34% |
| ADV of underlying (mns) | $50,643 |
Technical Indicators
| Recent close | $29.70 |
| 30d moving avg. | $32.37 |
| Annualized volatility | 16.4% |
| Relative strength (RSI) | 44 |
| Short interest (ETF) | 1.7% |
| Short interest (underlying) | 0.0% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. SYNB |
Expenses vs. SYNB |
ALTAR Score™ vs. SYNB |
|---|---|---|---|---|
| HELX | Franklin Genomic Advancements ETF | 32.8% | -20 bp | -2.7% |
| FHLC | Fidelity MSCI Health Care Index ETF | 21.3% | -62 bp | +3.0% |
| IYH | iShares U.S. Healthcare ETF | 20.8% | -30 bp | +3.6% |
| WDNA | WisdomTree BioRevolution Fund | 20.6% | -25 bp | -6.9% |
| VHT | Vanguard Health Care ETF | 19.8% | -60 bp | +2.7% |
| XLV | Health Care Select Sector SPDR Fund | 19.8% | -61 bp | +4.4% |
| VNSE | Natixis Vaughan Nelson Select ETF | 19.8% | +10 bp | +0.2% |
| RND | First Trust Bloomberg R&D Leaders ETF | 19.4% | -10 bp | +0.5% |
| FFOG | Franklin Focused Growth ETF FOCUSED GROWTH ETF | 19.3% | -9 bp | -0.2% |
| FMED | Fidelity Disruptive Medicine ETF | 19.1% | -20 bp | -3.4% |
Risk and Returns: SYNB vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
EPS Revision Activity (6 mo. ago = 100%)
Compound Annual Growth Rates
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| 2023 | 2024E | Fwd Est | 2025E | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/15/2024
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
SYNB
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
NEUTRAL
Average appreciation potential. A rating of NEUTRAL is assigned to ETFs with ALTAR Scores in the middle quintile (ranking between 40%-60%) of their category. This indicates that valuations adequately reflect the fundamentals of stocks in these funds.
ALTAR Score™
SYNB
3.1%
Cat. Avg
4.2%
ALTAR Score™ Calculation
Category Overview
There are 375 funds in the Global Equity category, with an average ALTAR Score™
of 4.2% and a standard deviation of
4.6%. SYNB's ALTAR Score™ is approximately
0.3 standard deviations
below
the category average. This places SYNB in the 40th percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
SYNBSELL
U/W
HOLD
O/W
BUY
Expense Analysis
| Peer Group | Rules-Based Global Equity ETFs |
| # of ETFs | 191 |
| Avg. Expense Ratio | 55.4 bp |
| Std. Deviation | 17.5 bp |
| SYNB (70 bp) Percentile rank | 80 |
Peer Group Expense Ratio Distribution
Total Cost of Ownership (TCO) Comparison
| Expense (bp) (A) |
Avg. Bid/Ask (bp) (B) |
TCO (bp) (A)+(B) |
|
|---|---|---|---|
| SYNB | 70.0 | 33.6 | 103.6 |
| Peer Avg. | 74.7 | 39.0 | 113.6 |
For a detailed cost analysis of this and any other ETF use the TCO Comparison Tool .